心脑清软胶囊联合匹伐他汀治疗高脂血症的临床研究
|
摘要
目的探讨心脑清软胶囊联合匹伐他汀治疗高脂血症的临床疗效。方法选取2017年7月—2018年7月在河北省第七人民医院进行治疗的88例高脂血症患者,根据住院号的奇偶数分为对照组和治疗组,每组各44例。对照组饭后口服匹伐他汀钙片,1片/次,1次/d。治疗组在对照组治疗基础上饭后口服心脑清软胶囊,2粒/次,3次/d。两组均治疗8周后进行效果比较。观察两组的临床疗效,比较两组治疗前后血脂指标、肥胖指标、血清学指标和氧化应激指标的变化情况。结果治疗后,对照组和治疗组的总有效率分别是81.82%、93.18%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均较治疗前显著降低,而高密度脂蛋白胆固醇(HDL-C)水平均增高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组TC、TG、LDL-C水平显著低于对照组,而HDL-C水平高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组体质量、肥胖度、体质量指数、体脂率都明显下降,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组这些肥胖指标明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组超敏C反应蛋白(hs-CRP)、肿瘤坏死因素-α(TFN-α)、干扰素-γ(IFN-γ)、嗜酸粒细胞阳离子蛋白(ECP)、总氧化态(TOS)水平均较治疗前显著下降,而总抗氧化态(TAS)和对氧磷酶-1(PON1)表达水平均增高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组hs-CRP、TFN-α、IFN-γ、ECP、TOS水平低于对照组,而TAS和PON1表达水平均高于对照组,两组比较差异具有统计学意义(P<0.05)。结论心脑清软胶囊联合匹伐他汀治疗高脂血症具有较好的临床疗效,可有效降低血脂水平和肥胖指标,改善机体炎症反应,改善机体氧化应激状态,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Xinnaoqing Soft Capsules combined with pitavastatin in treatment of hyperlipidemia. Methods Patients(88 cases) with hyperlipidemia in the Seventh People's Hospital of Hebei Province from July 2017 to July 2018 were divided into control(44 cases) and treatment(44 cases) groups according to the odd and even number of admission Numbers. Patients in the control group were po administered with Pitavastatin Calcium Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Xinnaoqing Soft Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the changes of blood lipid indicators, obesity indicators, serology and oxidative stress indicators in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the control and treatment groups were 81.82% and 93.18%, respectively, and there were differences between two groups(P < 0.05). After treatment, TC, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly increased, and there were differences in the same group(P < 0.05). After treatment, TC, TG, and LDL-C in the treatment group were lower than those in the control group, but HDL-C was higher than those in the control group, and there were differences between two groups(P < 0.05). After treatment, the body mass, obesity degree, body mass index and body fat rate in two groups decreased obviously, and there were differences in the same group(P < 0.05). After treatment, these obesity indexes in the treatment group were significantly lower than those in the control group, and there were differences between two groups(P < 0.05).After treatment, hs-CRP, TFN-α, IFN-γ, ECP, and TOS in two groups were significantly decreased, but TAS and PON1 were significantly increased, and there were differences in the same group(P < 0.05). After treatment, hs-CRP, TFN-α, IFN-γ, ECP, and TOS in the treatment group were lower than those in the control group, but TAS and PON1 were higher than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Xinnaoqing Soft Capsules combined with pitavastatin has significant effect in treatment of hyperlipidemia, and can effectively reduce the blood fat and obesity indicators, and improve the inflammatory response, also can improve the state of oxidative stress, which has a certain clinical application value.
Objective To investigate the clinical efficacy of Xinnaoqing Soft Capsules combined with pitavastatin in treatment of hyperlipidemia. Methods Patients(88 cases) with hyperlipidemia in the Seventh People's Hospital of Hebei Province from July 2017 to July 2018 were divided into control(44 cases) and treatment(44 cases) groups according to the odd and even number of admission Numbers. Patients in the control group were po administered with Pitavastatin Calcium Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Xinnaoqing Soft Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the changes of blood lipid indicators, obesity indicators, serology and oxidative stress indicators in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the control and treatment groups were 81.82% and 93.18%, respectively, and there were differences between two groups(P < 0.05). After treatment, TC, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly increased, and there were differences in the same group(P < 0.05). After treatment, TC, TG, and LDL-C in the treatment group were lower than those in the control group, but HDL-C was higher than those in the control group, and there were differences between two groups(P < 0.05). After treatment, the body mass, obesity degree, body mass index and body fat rate in two groups decreased obviously, and there were differences in the same group(P < 0.05). After treatment, these obesity indexes in the treatment group were significantly lower than those in the control group, and there were differences between two groups(P < 0.05).After treatment, hs-CRP, TFN-α, IFN-γ, ECP, and TOS in two groups were significantly decreased, but TAS and PON1 were significantly increased, and there were differences in the same group(P < 0.05). After treatment, hs-CRP, TFN-α, IFN-γ, ECP, and TOS in the treatment group were lower than those in the control group, but TAS and PON1 were higher than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Xinnaoqing Soft Capsules combined with pitavastatin has significant effect in treatment of hyperlipidemia, and can effectively reduce the blood fat and obesity indicators, and improve the inflammatory response, also can improve the state of oxidative stress, which has a certain clinical application value.
引文
[1]葛均波,徐永健.内科书[M].第8版.北京:人民卫生出版社,2013:227,765.
[2]周海洋,刘杰,任文刚.匹伐他汀钙片治疗高胆固醇血症的有效性和安全性研究[J].世界临床药物,2013,34(8):464-468.
[3]姜国志,李菲,刘鑫,等.五福心脑清软胶囊药效学研究进展及临床应用[J].现代中西医结合杂志,2016,25(15):1704-1706.
[4]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):399-401.
[5]孙明,王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010:147-148.
[6]刘志诚.肥胖病的针灸治疗[M].北京:人民卫生出版社,2008:12-17.
[7]刘志诚.肥胖病的针灸治疗[M].北京:人民卫生出版社,2008:12-17.
[8]蔡志友,晏勇,晏宁,等.血管性痴呆高脂血症患者血清HCY与hs-CRP临床研究[J].中国老年学杂志,2009,29(10):1231-1233.
[9]丁铭格.不同程度高脂血症患者血浆ONOO-、脂联素、TNF-α的变化及其临床意义[D].西安:第四军医大学,2012.
[10]杨钦灵,王立芳.NK细胞对妊娠期糖尿病高脂血症的影响[J].中国临床研究,2015,28(5):545-547.
[11]何丕,王祟忠,陈茂强,等.儿童腺样体肥大患者血清中TNF-α、IL-4、ECP水平及与肥大程度、体质量指数的关系[J].海南医学院学报,2015,21(5):686-688.
[12]陈娟,魏丹,马小安,等.肥胖哮喘患儿急性期血清趋化素水平改变及其临床意义研究[J].临床肺科杂志,2017,22(6):1070-1074.
[13]Ceron J J,Tecles F.Tvarijonaviciute,A.Serum paraoxonase 1(PON1)measurement:an update[J].BMCVet Res,2014,10(74):326-328.
[2]周海洋,刘杰,任文刚.匹伐他汀钙片治疗高胆固醇血症的有效性和安全性研究[J].世界临床药物,2013,34(8):464-468.
[3]姜国志,李菲,刘鑫,等.五福心脑清软胶囊药效学研究进展及临床应用[J].现代中西医结合杂志,2016,25(15):1704-1706.
[4]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):399-401.
[5]孙明,王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010:147-148.
[6]刘志诚.肥胖病的针灸治疗[M].北京:人民卫生出版社,2008:12-17.
[7]刘志诚.肥胖病的针灸治疗[M].北京:人民卫生出版社,2008:12-17.
[8]蔡志友,晏勇,晏宁,等.血管性痴呆高脂血症患者血清HCY与hs-CRP临床研究[J].中国老年学杂志,2009,29(10):1231-1233.
[9]丁铭格.不同程度高脂血症患者血浆ONOO-、脂联素、TNF-α的变化及其临床意义[D].西安:第四军医大学,2012.
[10]杨钦灵,王立芳.NK细胞对妊娠期糖尿病高脂血症的影响[J].中国临床研究,2015,28(5):545-547.
[11]何丕,王祟忠,陈茂强,等.儿童腺样体肥大患者血清中TNF-α、IL-4、ECP水平及与肥大程度、体质量指数的关系[J].海南医学院学报,2015,21(5):686-688.
[12]陈娟,魏丹,马小安,等.肥胖哮喘患儿急性期血清趋化素水平改变及其临床意义研究[J].临床肺科杂志,2017,22(6):1070-1074.
[13]Ceron J J,Tecles F.Tvarijonaviciute,A.Serum paraoxonase 1(PON1)measurement:an update[J].BMCVet Res,2014,10(74):326-328.